November 1979

Effects of Taurine on Seizures and Growth Hormone Release in Epileptic Patients

Author Affiliations

From the Edward Mallinckrodt Department of Pediatrics and the Department of Neurology and Neurosurgery, Washington University School of Medicine, and the Division of Neurology, St Louis Children's Hospital. Dr DeVivo is now with the Neurological Institute, Columbia-Presbyterian Medical Center, New York.

Arch Neurol. 1979;36(11):672-674. doi:10.1001/archneur.1979.00500470042006

• Oral taurine at doses of 375 to 8,000 mg/day (16 to 150 mg/kg/day) was administered to six patients with mixed seizure disorders refractory to standard anticonvulsant treatment. No improvement in seizure control was observed. During taurine tolerance testing, a substantial rise in plasma growth hormone concentration was noted in four of the six patients. Mean baseline concentrations of 3.0 ± 2.3 and 1.3 ± 0.9 ng/mL were increased to mean peak concentrations of 17.1 ± 2.4 (P <.005) and 20.4 ± 5.1 ng/ mL (P <.025), respectively. Cerebrospinal fluid homovanillic acid (HIV) concentration was also noted to be higher in two of three patients two weeks after initiation of taurine. Initial HVA concentrations of 20.3 and 28.2 ng/mL increased to 37.2 and 54.2 ng/mL, respectively. The possible effect of taurine on central dopaminergic mechanisms is discussed.